Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Co. Ltd
(OP:
ESALF
)
36.05
UNCHANGED
Last Price
Updated: 9:30 AM EDT, Aug 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eisai Co. Ltd
< Previous
1
2
3
Next >
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
July 26, 2024
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...
Via
Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
June 11, 2024
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting...
Via
Benzinga
Exposures
Product Safety
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.
Via
Talk Markets
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Via
Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu
Via
Benzinga
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
The U.S.
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:
Via
Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
September 25, 2023
Benzinga
Via
Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
September 25, 2023
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be
Via
Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck...
Via
Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and...
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow
Via
Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria
Via
Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Senator Bernie Sanders urged the U.S.
Via
Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for...
Via
Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of
Via
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...
Via
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.
Via
InvestorPlace
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Via
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab.
Via
Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.